Supplemental data and figures from Diversified local CRISPR–Cas immunity to viruses of Sulfolobus islandicus

• Main Authors: Pauly, Matthew D., Bautista, Maria A., Black, Jesse A., Whitaker, Rachel J.
• Format: Text
• Language: unknown
• Published: The Royal Society 2019
• Subjects: Microbiology; FOS Biological sciences; Evolutionary Biology; Kamchatka
• Online Access: https://dx.doi.org/10.6084/m9.figshare.7701047.v1; https://rs.figshare.com/articles/Supplemental_data_and_figures_from_Diversified_local_CRISPR_Cas_immunity_to_viruses_of_i_Sulfolobus_islandicus_i_/7701047/1

The population diversity and structure of CRISPR–Cas immunity provides key insights into virus–host interactions. Here, we examine two geographically and genetically distinct natural populations of the thermophilic crenarchaeon Sulfolobus islandicus and their interactions with Sulfolobus spindle-shaped viruses (SSVs) and S. islandicus rod-shaped viruses (SIRVs). We found that both virus families can be targeted with high population distributed immunity, whereby most immune strains target a virus using unique unshared CRISPR spacers. In Kamchatka, Russia, we observed high immunity to chronic SSVs that increases over time. In this context, we found that some SSVs had shortened genomes lacking genes that are highly targeted by the S. islandicus population, indicating a potential mechanism of immune evasion. By contrast, in Yellowstone National Park, we find high inter- and intra-strain immune diversity targeting lytic SIRVs and low immunity to chronic SSVs. In this population, we observed evidence of SIRVs evolving immunity through mutations concentrated in the first five bases of protospacers. These results indicate that diversity and structure of antiviral CRISPR–Cas immunity for a single microbial species can differ by both the population and virus type, and suggest that different virus families use different mechanisms to evade CRISPR–Cas immunity.This article is part of the theme issue ‘The ecology and evolution of prokaryotic CRISPR–Cas adaptive immune systems’.